Ideal Candidate Has Not Yet Undergone Drug Treatments
July 2, 2003
Patients in the early stages of MS, who haven't yet received the standard drug treatments to slow its debilitating effects, are considered prime candidates for a new drug study.
Multiple sclerosis affects 350,000 Americans. With the exception of trauma it's the most frequent cause of neurological disability beginning in early to middle adulthood. There is no cure.
But early studies show some promise for people with a certain kind of MS. The drug is called Campath 1H.
For more information about this drug and how to participate in the study,
please visit Study Details: http://www.theomahachannel.com/health/2308023/%20http://www.mult-sclerosis.org/Campath1H.html
Copyright © 2003, Internet Broadcasting Systems, Inc.